Parker Waichman Alonso LLP Urges FDA to Take Immediate Action on Yaz and Yasmin After Agency-Funded Study Confirms Drospirenone Contraceptives Raise Risk of Blood Clots

Share Article

Parker Waichman Alonso LLP, a National Law Firm, Urges the FDA to take Immediate Action to Protect Young Women from the Dangers Posed by Yaz, Yasmin and Other Drospirenone Birth Control Pills After Agency-Funded Study Confirms the Use of Such Medications Increase the Odds of Suffering a Dangerous Blood Clot.

Parker Waichman Alonso LLP urges the U.S. Food & Drug Administration (FDA) to quickly complete its ongoing safety review of Yaz, Yasmin and other birth control pills containing the synthetic progestin, drospirenone, in light of an FDA-funded study which confirms that women who use such medications face an increased risk of suffering a blood clot compared to women using other hormonal contraceptives made with an older progestin called levonorgestrel. In a report released October 27, the FDA warned that in the study, women taking pills with drospirenone were 75 percent more likely to experience clots compared to those taking other oral contraceptives. The FDA-funded study involved the medical histories of more than 800,000 American women, all of whom were on some type of birth control between 2001 and 2008.

This marks the second time since September 26, 2011 that the FDA has issued a warning regarding increased blood clots risks associated with drospirenone-containing birth control pills. The latest FDA warning also came just days after the British Medical Journal published a separate study out of Denmark which found that women taking birth control pills with newer progestins, including drospirenone, may double their risk of suffering a blood clot compared to women using other hormonal contraceptives made with levonorgestrel.

Despite these latest findings, the FDA has not advised women to stop using Yaz, Yasmin and other birth control pills made with drospirenone. However, the agency has scheduled a joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee for December 8, 2011, to discuss the safety of drospirenone birth control pills. In light of the most recent developments, Parker Waichman Alonso LLP urges the FDA to complete its ongoing drospirenone safety review as soon as possible and immediately take whatever action it deems necessary to protect young women from the serious risks posed by Yaz, Yasmin and similar birth control pills.

More than 9,000 lawsuits have been filed against Bayer Healthcare Pharmaceuticals, Inc., which markets Yaz and Yasmin in the United States, and Bayer Pharma AG, which manufactures drospirenone and ethinyl estradiol, the progestin and estrogen contained in Yaz and Yasmin, as well as other makers of drospirenone-containing birth control pills, by women who claim to have suffered strokes, pulmonary emboli, deep vein thrombosis, blood clots, gallbladder disease, and other serious injuries after taking these medications. Over 7,000 such lawsuits have been consolidated in the Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100) currently pending before the Honorable Judge David R. Herndon in the United States District Court for the Southern District of Illinois. Andres F. Alonso, Esq., a partner with Parker Waichman Alonso LLP, is serving as a member of the Plaintiffs Steering Committee in that litigation.

Parker Waichman Alonso LLP continues to offer free legal evaluations to victims of drospirenone contraceptives, including Yaz and Yasmin. If you or a loved one suffered a heart attack, blood clot or stroke while taking one of these birth control pills, please visit the firm's Yaz and Yasmin injury page at .

For more information regarding Yaz and Yasmin lawsuits and Parker Waichman Alonso LLP, please visit: or call 1-800-LAW-INFO (1-800-529-4636).

Contact:    Parker Waichman Alonso LLP
        David Krangle, Attorney
        (800) LAW-INFO
             (800) 529-4636


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dave Krangle
Visit website